An investigation of 4,500 individuals more than 13 years and distributed in the American Journal of Preventive Medicine reaches some astounding resolutions.

You are what you dont eat.

An eating regimen that assists individuals with decreasing hypertension or hypertension may likewise lessen the danger of cardiovascular breakdown in individuals younger than 75, as indicated by inquire about distributed in the June 2019 version of the American Journal of Preventive Medicine, and drove by specialists at Wake Forest School of Medicine, which is a piece of Wake Forest Baptist Health in Winston-Salem, N.C.

Just a couple earlier examinations have inspected the impacts of the Dash diet on the frequency of cardiovascular breakdown, and they have yielded clashing outcomes.

Claudia Campos, Wake Forest School of Medicine

An observational investigation of in excess of 4,500 individuals more than 13 years indicated that those people under 75 who most intently clung to the Dash diet had an altogether lower danger of creating cardiovascular breakdown than the individuals who were to the least extent liable to keep to the precepts of the eating regimen. (Run is an abbreviation for Dietary Approaches to Stop Hypertension.)

Just a couple earlier examinations have inspected the impacts of the Dash diet on the frequency of cardiovascular breakdown, and they have yielded clashing outcomes, said Claudia Campos, partner educator of general interior drug at Wake Forest School of Medicine. Following the Dash diet can lessen the danger of creating cardiovascular breakdown by practically half.

The investigation suggests removing five things of your eating regimen: This Dash diet prescribes organic products, vegetables, nuts, entire grains, poultry, fish and low-fat dairy items, while diminishing these three fundamental parts: salt, red meat, desserts and sugar-improved refreshments. It is fundamentally the same as the Mediterranean eating regimen, however the Dash diet prescribes removing two additional things: full cream (for low-fat dairy items) and mixed refreshments.

There are different approaches to eat more beneficial as well. Individuals who eat gradually are more averse to get stout or create metabolic disorder, a group of coronary illness, diabetes and stroke chance components, as indicated by explore introduced at the American Heart Associations Scientific Sessions 2017. They might be increasingly aware of what they are eating and drinking, and are less inclined to gorging.

The Dash diet is fundamentally the same as the Mediterranean eating regimen be that as it may, in contrast to that diet, it prescribes low-fat dairy items and barring mixed drinks.

Dietitians additionally exhort against nibbling and takeouts. Individuals have less command over what goes into their dinners when they request in. Americans get the vast majority of their day by day sodium over 75% from prepared nourishment and eatery nourishment, as indicated by the Centers for Disease Control and Prevention. Individuals eat a normal of 200 calories more for every feast when they eat nourishment from eateries..

Abundance sodium can build your circulatory strain and your hazard for a coronary illness and stroke, the Centers for Disease Control and Prevention says. Together, coronary illness and stroke execute a greater number of Americans every year than some other reason. Americans get 71% of their every day sodium from prepared and café nourishment. Cooking for yourself is the most secure and most advantageous alternative.

Falsely improved drinks might be connected to an expanded danger of stroke and dementia, as indicated by the American Heart Associations peer-inspected diary Stroke. Another 2015 examination found that more seasoned ladies who devour at least two eating regimen soft drinks every day are 30% bound to endure a cardiovascular occasion. Add that to more research recommending standard soft drink is connected to weight.

The post 5 Right now, slash your diet to reduce high blood pressure and reduce the risk of heart failure appeared first on MyMedicPlus.

A group of medical researchers in Maryland believe the answer for curing HIV/AIDS may be gene therapy.

American Gene Technologies (AGT), a Rockville-based medical research company, has submitted a Investigational New Drug (IND) application with the FDA to begin gene therapy trials that researchers believe could eliminate HIV in people already living with the virus.

The drug—an HIV treatment program called AGT103-T—is a single-dose, lentiviral vector-based gene therapy that AGT says could remove infected cells from the body and decrease or eliminate the need for lifelong antiretroviral treatment in HIV-positive patients.

If approved, the company hopes to begin a Phase 1 clinical trial that will examine the safety of AGT103-T in humans.

In a press statement, AGT chief science officer C. David Pauza, PhD, said the company’s objective is “to treat HIV disease with an innovative cell and gene therapy that reconstitutes immunity to HIV and will control virus growth in the absence of antiretroviral drugs.”

AGT’s approach differs from other medical researchers’ attempts to cure HIV. As NewNowNext reported earlier this year, researchers in Europe made headlines when two separate HIV-positive patients no longer had the virus after obtaining bone marrow transplants from donors with an HIV-resistant mutation to treat unrelated cancers.

Those patients marked the second and third time doctors were able to effectively “cure” patients living with HIV via bone marrow transplant in the history of modern medicine. However, HIV/AIDS activists and medical professionals were quick to raise concerns about the feasibility of curing HIV with bone marrow transplants on a more widespread basis.

Kenneth Freedberg, MD, a professor of medicine at Harvard Medical School and Massachusetts General Hospital, told NewNowNext in March that the method “is not a remotely plausible strategy for HIV treatment” for the vast majority of patients.

“A bone marrow transplant is an extraordinarily toxic and life-threatening intervention, which you do if someone has an illness that’s clearly going to be fatal,” Freedberg explained. “There must be no other treatment options available. It puts people at massive risk for infections and toxicity complications.”

As the fight against HIV/AIDS wages on, communities at risk of contracting the virus continue to take preventative measures against new infections—including daily use of Pre-exposure prophylaxis (PrEP), a potentially life-saving HIV prevention drug that is massively popular among gay, bisexual, and queer men.

In the United States, PrEP is pretty much exclusively available as Truvada, its brand-name version manufactured by Gilead Sciences with a very high retail markup. That may change soon, though: Earlier this week, the government filed a lawsuit against Gilead alleging patent infringement on PrEP, which was patented by public health researchers at the Department of Health and Human Services years ago.

The post Gene Tech Company Claims to Have Found a Cure for HIV/AIDS appeared first on MyMedicPlus.

Taking blood pressure medication at bedtime rather than on waking halves the risk of events such as heart attack and stroke, a major study has revealed.

Experts say the findings could potentially transform the way such medications are prescribed, but questions remain, not least why taking the medication at night has such a profound effect.

Prof Ramón Hermida, first author of the study from the University of Vigo in Spain, said the effect was thought to be down to the body’s internal clock that means processes and chemicals within our bodies vary over a 24-hour period.

The upshot, he said, was that the same drug could have vastly different effects if taken at a different point in time, something that has been dubbed “chronotherapy”.

“The same antihypertensive medication, the same molecule, at the same dose, ingested at two different times have totally different pharmacokinetics and pharmacodynamics and therefore they behave as two totally different medications,” said Hermida.

Previous research has shown that high blood pressure during sleep, and only small differences between blood pressure during the day and night, are both important risk factors for cardiovascular problems.

There have also been studies suggesting blood pressure medications are more effective when taken in the evening and might result in fewer heart attacks and strokes.

As a result, the team set out to compare the long-term implications of adopting a bedtime, rather than waking time, routine for taking blood pressure medication in a large trial.

Writing in the European Heart Journal, the team report how they randomly split more than 19,000 adults with high blood pressure into two groups. Half of the patients were asked to take all their medication at bedtime while the other half were asked to take it upon waking.

Crucially, said Hermida, fixed times were not given so that participants took their medication at the same point in the daily routine.

The patients were then followed for between four and eight years, with blood pressure measured over a 48-hour period at the outset and at least once a year during the study. In total 1,752 cardiovascular events such as heart attack, stroke, death from cardiovascular disease and heart failure were recorded during the study.

While the impact on daytime blood pressure was similar, those taking their medication at bedtime had a small but significantly greater reduction in blood pressure during sleep compared with those taking medication on waking, as well as a greater difference in blood pressure when sleeping compared with being awake.

Among possible explanations, Hermida said it was known that the hormone system that regulates blood pressure peaks in activity during sleep, meaning it might be that medications that interact with this system have a greater effect when taken just before bed.

After taking into account factors such as age, sex, smoking status, history of cardiovascular events and typical decrease in blood pressure when asleep, the team found patients who took their medication at bedtime had a 56% lower risk of death from cardiovascular disease, a 49% lower risk of stroke and a 44% lower risk of heart attack compared with the other group.

The team say the findings need to be confirmed in a more diverse range of ethnicities, while it is not clear if they would hold among those undertaking shift work.

Prof Stephen MacMahon, the principal director of the George Institute for Global Health at Oxford University, who was not involved in the study, said such a profound effect on cardiovascular events was surprising given the modest differences in blood pressure.

However, Hermida said the blood pressure medication could be operating on many different biological processes that vary in their activity over the course of the day.

Besides the effect on blood pressure, the team found those who took the medication at bedtime also showed better kidney function and cholesterol measures, both of which are important factors when it comes to cardiovascular disease.

Paul Leeson, a professor of cardiovascular medicine at Oxford University, said the next step was to unpick why the timing of the medication had such an effect, something that could soon become clear with results from other big studies.

“This study has the potential to transform how we prescribe blood pressure medication,” he said.

The post Blood pressure drugs work far better if taken at night, study shows appeared first on MyMedicPlus.

Researchers at The Westmead Institute for Medical Research have discovered brand new immune cells that are at the frontline of HIV infection. Known as CD11c+ dendritic cells, these new cells are more susceptible to HIV infection and can then transmit the virus to other cells.

CD11c+ dendritic cells are a subset of dendritic cells (a type of immune cell) that are only found in human genital tissues, specifically at the epithelial level (the thin layer of tissue that forms the surface) of the vagina, inner foreskin and anus. This location in genital tissue often means that these newly discovered CD11c+ dendritic cells are the first immune cells to interact with HIV.

One of the lead researchers on this project, Associate Professor Andrew Harman from The Westmead Institute for Medical Research says that the role of these newly discovered CD11c+ dendritic cells is to capture any incoming disease-causing virus or bacteria (pathogen), and then deliver it to CD4 T cells.

“CD4 T cells are responsible for driving an immune response to the pathogen. Interestingly, they are also the primary HIV target cells in which the virus replicates.

“Once dendritic cells capture a pathogen, they communicate what they have found to CD4 T cells in the lymph nodes, essentially giving the immune system a constant update. This information prepares the immune system to either tolerate a bacteria or virus, or attack it.

“However, if CD4 T cells fall below critical levels (e.g. in HIV positive patients), then the body is no longer able to mount an immune response, leading to a diagnosis of AIDS.

“Our research team has shown that the newly discovered CD11c+ dendritic cells are more susceptible to HIV infection than any other known dendritic cell. We have also shown that CD11c+ dendritic cells interact with CD4 T cells more efficiently than any other dendritic cells. Importantly CD11c+ dendritic cells transfer the virus to CD4 T cells, making them key drivers of HIV infection. As these dendritic cells are so efficient at interacting with CD4 T cells, they are also important vaccine candidates.

The team from The Westmead Institute for Medical Research were able to discover these CD11c+ dendritic cells using donated genital tissues.

Associate Professor Harman says, “We were able to look at the tissue only 30 minutes after it had been surgically removed from the body and also developed ground breaking RNAscope technology which allowed us to watch as living CD11+c dendritic cells took up the virus and delivered it to the CD4 T cells,” says Associate Professor Harman.

According to co-lead author and Executive Director of The Westmead Institute for Medical Research, Professor Tony Cunningham, this discovery has unlocked two new avenues for medical researchers to pursue in the search for more effective HIV treatments.

“This finding opens up a potential for the development of strategies to block the transmission of HIV. If we can block HIV’s ability to bind to the CD11+c dendritic cells, which are often the first immune cells to encounter the HIV virus, then we can stop their ability to transmit the virus to the CD4T cells. In a situation where there are low levels of CD4 T cells, this could stop the virus from spreading.

“Another avenue is to use this new information to develop a HIV vaccine. If HIV fragments or inactivated HIV were targeted at these CD11+c dendritic cells, this would have the potential to prime an immune response against HIV as soon as it enters the body,” says Professor Cunningham.

The post Newly discovered immune cells at the frontline of HIV infection appeared first on MyMedicPlus.